Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot, two viruses: vaccine aims to shield older adults from RSV and HMPV

NCT ID NCT07810010

Vaccine Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

Researchers are testing a single injection vaccine designed to protect adults 60 and older from two respiratory viruses: RSV and HMPV. The trial plans to enroll about 8,000 participants who will randomly receive either the vaccine or a placebo. Scientists will track who develops lower respiratory tract disease from either virus, and they will monitor safety and immune responses. A small safety group receives the first doses before the larger group joins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a bivalent protein vaccine candidate against RSV and HMPV
What this could lead to
If it works, one shot could protect older adults from two common respiratory viruses that cause serious lung infections. This could simplify prevention by covering RSV and HMPV at the same time.
What could go wrong
This is a Phase 2b trial, so researchers still need to confirm whether the vaccine lowers infection rates in real life. The vaccine may not produce strong enough protection in older adults, and any immune response could fade over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 8,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 60 years or older on the day of inclusion * Participants who, as determined by medical evaluation including medical history, physical examination, and clinical judgment of the Investigator are eligible for inclusion Exclusion Criteria: * Known/suspected immunodeficiency; immunosuppressive therapy/immunomodulators in past 6 months; long-term systemic corticosteroids (eg, prednisone for more than 2 weeks in past 3 months); history of immune-mediated neurological disease. Of note, persons living with stable HIV are not excluded * Known systemic hypersensitivity to any of the study intervention components or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion * Previous history of Guillain-Barré Syndrome (GBS) * Previous vaccination against RSV and/or HMPV (with a licensed or investigational vaccine either as a monovalent vaccine or any combination of the antigens) or previous receipt of RSV and/or HMPV monoclonal antibody The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers Human metapneumovirus Respiratory syncytial virus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    16 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number : 0360002

    RECRUITING

    Albion, Queensland, 4010, Australia

  • Investigational Site Number : 0360003

    RECRUITING

    Sippy Downs, Queensland, 4556, Australia

  • Investigational Site Number : 0360006

    RECRUITING

    Blacktown, New South Wales, 2148, Australia

  • Investigational Site Number : 0360007

    RECRUITING

    Maroubra, New South Wales, 2035, Australia

  • Investigational Site Number : 0360008

    RECRUITING

    Bruse, Australian Capital Territory, 2617, Australia

  • Investigational Site Number : 0360009

    RECRUITING

    Melbourne, Victoria, 3124, Australia

  • Investigational Site Number : 8260002

    RECRUITING

    Blackpool, Lancashire, FY3 7EN, United Kingdom

  • Investigational Site Number : 8260004

    RECRUITING

    London, SW10 0LR, United Kingdom

  • Investigational Site Number : 8260005

    RECRUITING

    Witney, Oxfordshire, OX28 6JS, United Kingdom

  • Investigational Site Number : 8260006

    RECRUITING

    West Kirby, Wirral, CH48 5AA, United Kingdom

  • Investigational Site Number : 8260007

    RECRUITING

    London, London, City of, NW10 2PB, United Kingdom

  • Investigational Site Number : 8260011

    RECRUITING

    London, England, SW10 9NH, United Kingdom

  • Investigational Site Number : 8260012

    RECRUITING

    Cardiff, Cardiff [Caerdydd Gb-crd], CF15 9SS, United Kingdom

  • Investigational Site Number : 8261010

    RECRUITING

    Bournemouth, Dorset, BH7 7DW, United Kingdom

  • Investigational Site Number : 8262010

    RECRUITING

    Portsmouth, Hampshire, PO6 3LY, United Kingdom

  • Investigational Site Number : 8263010

    RECRUITING

    Dorchester, Dorset, DT1 2JY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.